Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACELYRIN, INC. (SLRN)
NASDAQ:SLRN
SLRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.85 - $8.89
Previous CloseN/A
Volume2.42M
Average Volume (3M)2.62M
Market Cap
$218.52M
Enterprise Value-$63.63M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Mar 27, 2025EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.68
Shares Outstanding100,702,250
10 Day Avg. Volume5,430,748
30 Day Avg. Volume2,618,049
Standard Deviation0.24
R-Squared0.08
Alpha-0.11
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit553.26
Enterprise Value/Ebitda0.19
Forecast
1Y Price Target
$8.50Price Target Upside226.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
ACELYRIN, INC. News
PremiumCompany Announcements
ACELYRIN, INC. Announces Merger with Alumis Inc.
PremiumCompany Announcements
ACELYRIN, INC. Ends Key Agreement with Affibody
---
Bulls Say, Bears Say
Bulls Say
Efficacy PotentialThe Ph3 regimen of 100mg LD + 50mg Q2W could potentially increase drug exposure, possibly boosting its efficacy.
Long-term TreatmentAll patients will be able to receive loni after 24 weeks through 52 weeks of treatment, allowing for potentially longer-term treatment compared to fixed dose regimens.
Safety ProfileLoni's safety profile looks promising versus competitors, with no dose dependent adverse effects seen.
Bears Say
Capital InvestmentLack of catalysts ahead of Ph3 loni data and heavy capital investment required to run two Ph3 TED trials will continue to weigh on shares.
Dosing ConcernsConcerns exist on a more frequent dosing interval for lonigutamab versus subQ competition.
Efficacy UncertaintyShares are weak post the disclosure on the selection of Q2W for the Ph3 dosing regimen and uncertainty surrounding efficacy expectations for a Ph3 dose not tested in the Ph1b/2 study.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SLRN FAQ
What was ACELYRIN, INC.’s price range in the past 12 months?
ACELYRIN, INC. lowest stock price was $1.84 and its highest was $8.88 in the past 12 months.
What is ACELYRIN, INC.’s market cap?
ACELYRIN, INC.’s market cap is $218.52M.
When is ACELYRIN, INC.’s upcoming earnings report date?
ACELYRIN, INC.’s upcoming earnings report date is Mar 27, 2025 which is in 32 days.
How were ACELYRIN, INC.’s earnings last quarter?
ACELYRIN, INC. released its earnings results on Nov 13, 2024. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.309.
Is ACELYRIN, INC. overvalued?
According to Wall Street analysts ACELYRIN, INC.’s price is currently Undervalued.
Does ACELYRIN, INC. pay dividends?
ACELYRIN, INC. does not currently pay dividends.
What is ACELYRIN, INC.’s EPS estimate?
ACELYRIN, INC.’s EPS estimate is -0.82.
How many shares outstanding does ACELYRIN, INC. have?
ACELYRIN, INC. has 100,702,250 shares outstanding.
What happened to ACELYRIN, INC.’s price movement after its last earnings report?
ACELYRIN, INC. reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went down -13.712%.
Which hedge fund is a major shareholder of ACELYRIN, INC.?
Currently, no hedge funds are holding shares in SLRN
---
ACELYRIN, INC. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (226.92% Upside)
$8.50 (226.92% Upside)
Hedge Fund Trend
Decreased
By 357.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.96%
12-Months-Change
Fundamentals
Return on Equity
-41.95%
Trailing 12-Months
Asset Growth
-22.76%
Trailing 12-Months
Company Description
ACELYRIN, INC.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
---
SLRN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant progress in pipeline prioritization and financial management, offset by challenges in clinical development decisions and safety considerations.Read More>---
SLRN Stock 12 Month Forecast
Average Price Target
$8.50
▲(226.92% Upside)
Technical Analysis
Best Analysts Covering SLRN
1 Year
1 Year Success Rate
2/16 ratings generated profit
1 Year Average Return
-45.93%
reiterated a buy rating 16 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -45.93% per trade.
---